Roxadustat

證據等級: L5

預測適應症: 10 個

Roxadustat: From Chronic Kidney Disease Anemia to Dry Eye Syndrome

One-Sentence Summary

Roxadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) originally developed to treat anemia associated with chronic kidney disease (CKD). The TxGNN model predicts it may also be effective for Dry Eye Syndrome, but this direction is currently supported by only 1 observational clinical trial and no published literature, making the evidence base very weak at this stage.

Quick Overview

Item	Content
Original Indication	Anemia associated with chronic kidney disease (CKD)
Predicted New Indication	Dry Eye Syndrome
TxGNN Prediction Score	99.51%
Evidence Level	L4
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from official sources is not available. Based on known information, Roxadustat is a HIF prolyl-hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factor to stimulate endogenous erythropoietin production, and its efficacy in CKD-associated anemia is well established.

The proposed link to dry eye syndrome is indirect: the HIF signaling pathway is known to play a physiological role in corneal epithelial repair and in lipid metabolism within the meibomian glands, which are central to tear-film stability. In theory, a HIF-stabilizing agent could influence ocular surface health through this pathway.

However, this is a mechanistic hypothesis rather than a demonstrated treatment effect. The only available clinical trial identified is an observational study characterizing meibomian gland function in patients with renal anemia (a population that happens to include Roxadustat users) — it does not test Roxadustat as an intervention for dry eye syndrome. The connection should therefore be regarded as biologically plausible but clinically unproven.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06287879	Phase NA	Unknown	50	Observational study of meibomian gland function/morphology in renal anemia patients (a population commonly treated with EPO or Roxadustat); dry eye symptoms were a presenting feature in patients referred to ophthalmology. Not an interventional trial of Roxadustat for dry eye syndrome — relevance graded C (indirect, non-interventional).

Literature Evidence

Currently no related literature available.

Denmark Market Information

Roxadustat is not currently marketed in Denmark, and no marketing authorisations (national or centralised/EMA) are on record.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No warnings, contraindications, or drug interaction data were retrievable in this evidence pack.

Note: for the HIF-PHI class generally, malignancy-related risk has been flagged as a labeling/monitoring concern in other jurisdictions — this should be verified against the official Danish/EU product information before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The dry eye syndrome prediction rests on a high TxGNN score but is backed only by an observational trial with no interventional or mechanistic-treatment data, and no supporting literature. Combined with the absence of Danish market authorisation and missing core safety documentation, there is currently insufficient evidence to advance this candidate.

To proceed, the following is needed:

Official mechanism of action (MOA) data from DrugBank or SmPC
SmPC-derived warnings and contraindications (currently a blocking data gap for safety pre-screening)
Interventional (not merely observational) clinical evidence specifically testing Roxadustat in dry eye syndrome
Confirmation of Danish/EU regulatory status and any HIF-PHI class-specific malignancy monitoring requirements before safety evaluation can proceed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.